Merck reported strong revenue and EPS growth, driven by the expanding KEYTRUDA portfolio and robust sales in vaccines and animal health. Management's optimistic guidance and strategic investments in high-growth areas are likely to enhance investor confidence, despite some margin pressures.

[1]